| Alumis Reports First Quarter 2025 Financial Results and Highlights Recent Achievements |
SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the quarter ended March 31, 2025, and highlighted recent achievements and upcoming milestones. |
globenewswire.com |
2025-05-14 20:05:00 |
Czytaj oryginał (ang.) |
| Alumis Stockholders Approve Merger with ACELYRIN |
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. |
globenewswire.com |
2025-05-13 17:00:00 |
Czytaj oryginał (ang.) |
| Alumis and ACELYRIN Announce Amended Merger Agreement |
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis Merger maximizes the potential value for ACELYRIN stockholders and creates a stronger combined company, best-positioned to realize long-term value of multiple late-stage assets ACELYRIN files investor presentation highlighting benefits of proposed merger and comprehensive Board process Special Meeting of Stockholders for both companies to be held May 13, 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 21, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and ACELYRIN, INC. |
globenewswire.com |
2025-04-21 10:30:00 |
Czytaj oryginał (ang.) |
| ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (NasdaqGS: SLRN) to Alumis Inc. (NasdaqGS: ALMS). Under the terms of the proposed transaction, shareholders of Acelyrin will receive 0.4274 shares of Alumis common stock for each share of Acelyrin that they own. KSF is seeking to determine whether this consideration and the process that led to i. |
businesswire.com |
2025-04-16 21:31:00 |
Czytaj oryginał (ang.) |
| 3 Biopharmaceutical Stocks Bucking the Sell-Off |
With tariffs sending markets reeling in the first days of the second quarter—the S&P 500 dropped roughly 10% in the five trading periods through Apr. 7, 2025—investors with cash to spend might be looking for an opportunity. While it's true that some of the biggest firms in the world started April with major share price discounts, investors may want to find companies to target that have been more or less bulletproof in the extreme uncertainty characterizing the market. |
marketbeat.com |
2025-04-10 11:02:06 |
Czytaj oryginał (ang.) |
| Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger |
Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Boards unanimously recommend stockholders vote “FOR” the merger Transaction expected to be completed in second quarter of 2025 SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, April 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and ACELYRIN, INC. |
globenewswire.com |
2025-04-04 20:34:00 |
Czytaj oryginał (ang.) |
| Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan |
- Alumis to receive $40 million in upfront and near-term co-development payments, with potential for approximately $140 million in additional milestone and field option payments, plus tiered royalties on future sales -Deal underscores the commercial potential of Alumis' ESK-001 and leverages Kaken's regional capabilities and expertise in novel dermatology treatments -Kaken has the option to license ESK-001 for further clinical development and commercialization in rheumatological and gastrointestinal diseases SOUTH SAN FRANCISCO, Calif. and BUNKYO-KU, Tokyo, March 25, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, and Kaken Pharmaceutical Co., Ltd. |
globenewswire.com |
2025-03-25 04:30:00 |
Czytaj oryginał (ang.) |
| Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements |
– Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD program data readout now expected 1Q 2026 – – Presented Phase 1 clinical data at ACTRIMS 2025 demonstrating first-in-class oral TYK2 inhibitor A-005 has ability to cross blood-brain barrier and was well tolerated; Phase 2 in MS to begin 2H 2025 – – Announced merger agreement with ACELYRIN to create combined company with differentiated late-stage portfolio of therapies and strong balance sheet; expected to close 2Q 2025 – SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the year ended December 31, 2024, and highlighted recent achievements and upcoming milestones. |
globenewswire.com |
2025-03-19 18:05:00 |
Czytaj oryginał (ang.) |
| Alumis to Present at Leerink's 2025 Global Healthcare Conference |
SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will participate in a fireside chat at Leerink's 2025 Global Healthcare Conference on Tuesday, March 11, 2025 at 10:40 am ET. |
globenewswire.com |
2025-03-10 10:00:00 |
Czytaj oryginał (ang.) |
| Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis |
ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at AAD 2025 |
globenewswire.com |
2025-03-08 11:00:00 |
Czytaj oryginał (ang.) |
| Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger |
SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis”) and ACELYRIN, INC. |
globenewswire.com |
2025-03-04 11:01:00 |
Czytaj oryginał (ang.) |
| ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger |
All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders LOS ANGELES, March 04, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, after due consideration in consultation with its independent financial and legal advisors, its Board of Directors determined that the unsolicited indication of interest from Concentra Biosciences, LLC, of which Tang Capital Partners, LP is the controlling shareholder, is not reasonably expected to result in a superior proposal to the planned merger with Alumis Inc. (Nasdaq: ALMS). |
globenewswire.com |
2025-03-04 11:00:00 |
Czytaj oryginał (ang.) |
| Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout |
– Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension (OLE) study in adults with moderate-to-severe plaque psoriasis – – Additional Phase 2 e-poster presentations to describe patient-reported outcomes, disease biomarker activity and pharmacokinetic data of ESK-001 in psoriasis patients – – Phase 3 ONWARD program topline data now expected in Q1 2026 – SOUTH SAN FRANCISCO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced the Company will give four data presentations from its Phase 2 OLE study evaluating ESK-001, a next-generation oral tyrosine kinase 2 (TYK2) inhibitor, in moderate-to-severe psoriasis (PsO) patients at the 2025 American Academy of Dermatology (AAD) annual meeting from March 7 to 11, 2025, in Orlando, Florida. |
globenewswire.com |
2025-02-28 11:08:00 |
Czytaj oryginał (ang.) |
| Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases |
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS) (“Alumis” or the “Company”), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced the Company will give two data presentations on A-005, a potent, selective, central nervous system (CNS) penetrant tyrosine kinase 2 (TYK2) inhibitor, on Friday, February 28, 2025, at the 10th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2025. |
globenewswire.com |
2025-02-27 18:15:00 |
Czytaj oryginał (ang.) |
| Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference |
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will present at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11, 2025 at 3:20 pm ET. |
globenewswire.com |
2025-02-10 18:45:00 |
Czytaj oryginał (ang.) |
| ACELYRIN INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Acelyrin, Inc. - SLRN |
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Acelyrin, Inc. (NasdaqGS: SLRN) to Alumis Inc. (NasdaqGS: ALMS). Under the terms of the proposed transaction, shareholders of Acelyrin will receive 0.4274 shares of Alumis common stock for each share of Acelyrin that they own. KSF is seeking to determine whether this consideration and the process that led to i. |
businesswire.com |
2025-02-10 14:16:00 |
Czytaj oryginał (ang.) |
| ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of ACELYRIN, INC. |
NEW YORK , Feb. 7, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by ACELYRIN, INC. (NASDAQ: SLRN) and its board of directors concerning the proposed acquisition of the company by Alumis Inc. (NASDAQ: ALMS). |
prnewswire.com |
2025-02-07 17:22:00 |
Czytaj oryginał (ang.) |
| ALMS Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Alumis Inc. is Fair to Shareholders |
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Alumis Inc. (NASDAQ: ALMS) and ACELYRIN, INC. is fair to Alumis shareholders. Upon closing of the proposed transaction, Alumis shareholders will own approximately 55% of the combined company. Halper Sadeh encourages Alumis shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com. |
businesswire.com |
2025-02-06 23:50:00 |
Czytaj oryginał (ang.) |
| Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases |
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Company Developing and Commercializing Transformative Therapies for Immune-mediated Diseases |
globenewswire.com |
2025-02-06 18:15:00 |
Czytaj oryginał (ang.) |
| Alumis Strengthens Leadership Team with Key Appointments |
Jack Danilkowicz appointed as Chief Commercial Officer; bringing extensive experience successfully planning and executing commercial strategies at global biopharmaceutical companies Sara Klein promoted to Chief Legal Officer; leveraging deep expertise advising biopharmaceutical companies on legal matters across all stages of development and growth SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that it has strengthened its leadership team with key appointments to support its transition to a late-stage company. |
globenewswire.com |
2025-01-28 10:00:00 |
Czytaj oryginał (ang.) |
| Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements |
– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, including global Phase 3 ONWARD clinical trials for ESK-001 in moderate-to-severe plaque psoriasis, Phase 2b clinical trial for ESK-001 in systemic lupus erythematosus (SLE) and Phase 1 clinical study for A-005 being developed for neuroinflammatory and neurodegenerative diseases – SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and highlighted recent achievements and upcoming milestones. |
globenewswire.com |
2024-11-13 18:05:00 |
Czytaj oryginał (ang.) |
| Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside |
HC Wainwright has initiated coverage on Alumis Inc. ALMS, a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. |
benzinga.com |
2024-10-17 18:32:11 |
Czytaj oryginał (ang.) |
| Alumis: Could This Broken Immunology IPO Become The Next Amgen? |
With a drug in advanced testing for two different indications that have spawned several blockbuster drugs, could Alumis be the next immunology stock to soar on the Nasdaq? Investors who buy now can get it around 30% under the June 28th IPO price. Alumis is backed by prominent healthcare hedge funds such as Baker Brothers, VenBio, and Cormorant Asset Management. |
seekingalpha.com |
2024-10-04 06:00:00 |
Czytaj oryginał (ang.) |
| Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study |
28-week data show ESK-001 was generally well tolerated and most patients treated with the top dose of 40 mg twice daily achieved PASI 75 Three additional data presentations further support ESK-001's potential to offer a highly differentiated and best-in-class treatment profile for people with moderate-to-severe plaque psoriasis Full 52-week Phase 2 OLE dataset expected 1H 2025; Phase 3 clinical program ongoing SOUTH SAN FRANCISCO, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced positive 28-week data from the open-label extension (OLE) period of its Phase 2 STRIDE clinical trial of ESK-001. |
globenewswire.com |
2024-09-27 13:00:00 |
Czytaj oryginał (ang.) |
| Alumis: Recent IPO With Differentiated Data In Autoimmune Diseases |
Alumis, a recent IPO, has ESK-001, a promising phase 3 TYK2 inhibitor for Psoriasis and SLE, showing superior efficacy and safety over existing treatments. ESK-001's allosteric inhibition offers high selectivity and minimal off-target effects, potentially positioning it as a better alternative to the approved TYK2 inhibitor, Sotyktu. Despite strong midstage trial data and a solid cash runway, the highly competitive market and recent IPO status present significant investment risks. |
seekingalpha.com |
2024-09-16 20:32:08 |
Czytaj oryginał (ang.) |
| Alumis to Participate in Upcoming September Investor Conferences |
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that company management will participate in the following investor conferences in September: Morgan Stanley 22nd Annual Global Healthcare ConferenceThursday, September 5, 2024, 8:30 am ETNew York, NY Format: fireside chat and one-on-one investor meetings 2024 Wells Fargo Healthcare ConferenceFriday, September 6, 2024Boston, MA Format: one-on-one investor meetings only Baird 2024 Global Healthcare ConferenceWednesday, September 11, 2024, 8:30 am ETNew York, NY Format: presentation and one-on-one investor meetings; archived webcast replay on Investor Events page of Alumis website for 90 days following the conference 2024 Cantor Fitzgerald Global Healthcare ConferenceTuesday, September 17, 2024, 10:55 am ETNew York, NY Format: fireside chat and one-on-one investor meetings; live webcast on Investor Events page of Alumis website, archived replay available for 90 days following the presentation Stifel 2024 Immunology and Inflammation Virtual SummitWednesday, September 18, 2024, 10:00 am ET Format: presentation About Alumis Alumis is a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases. |
globenewswire.com |
2024-09-03 20:29:00 |
Czytaj oryginał (ang.) |
| Alumis Reports Second Quarter 2024 Financial Results and Highlights Recent Development and Corporate Achievements |
– Initiated patient dosing in ESK-001 Phase 3 ONWARD clinical program in moderate-to-severe plaque psoriasis – – Initiated Phase 1 clinical trial for A-005 in healthy participants – – Completed IPO and private placement raising gross proceeds of $250M – SOUTH SAN FRANCISCO, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2024, and provided a summary of recent corporate achievements and upcoming milestones. |
globenewswire.com |
2024-08-13 20:05:00 |
Czytaj oryginał (ang.) |
| Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis |
– Co-primary endpoint of PASI 75 and sPGA 0/1 score at 24 weeks to serve as basis for U.S. regulatory submission – – Pivotal Phase 3 program supported by positive Phase 2 STRIDE clinical data as well as ongoing open-label extension (OLE) study – – Topline data anticipated in 2026 – SOUTH SAN FRANCISCO, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that patient dosing has commenced in the ONWARD Phase 3 clinical program. |
globenewswire.com |
2024-07-29 12:00:00 |
Czytaj oryginał (ang.) |
| Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation |
Guggenheim Partners initiated coverage on Alumis Inc. ALMS, a clinical-stage biopharmaceutical company developing oral therapies for immune-mediated diseases. |
benzinga.com |
2024-07-24 19:18:10 |
Czytaj oryginał (ang.) |
| U.S. IPO Weekly Recap: 2Q IPO Market Closes Out With Sizable Pricings And Pipeline Additions |
The IPO market closed out June with four deals, three of which raised $100+ million. In the pipeline, nine companies submitted initial filings, led by what could be the largest IPO of 2024 to date. Web comic platform WEBTOON Entertainment (WBTN) led the week's deals, pricing at the high end to raise $315 million at a $2.8 billion market cap. |
seekingalpha.com |
2024-07-01 15:51:00 |
Czytaj oryginał (ang.) |
| Immune Disease-Focused Alumis Raises $250M In Downsized Initial Public Offering |
On Friday, Alumis Inc ALMS priced its initial public offering at $16/share, the low end of the range of $16 to $18, raising $210 million via 13.13 million shares offering. |
benzinga.com |
2024-06-28 17:36:06 |
Czytaj oryginał (ang.) |
| Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut |
Shares of biopharmaceutical firm Alumis opened nearly 16% below their initial public offering (IPO) price in their debut on the Nasdaq on Friday. |
reuters.com |
2024-06-28 16:58:46 |
Czytaj oryginał (ang.) |
| Therapy developer Alumis prices U.S. IPO at about $902 mln valuation |
Alumis set the pricing of its U.S. initial public offering at $16 per share, the lower end of its price range, valuing it at around $902 million. |
reuters.com |
2024-06-28 04:43:47 |
Czytaj oryginał (ang.) |
| Alumis Announces Pricing of Initial Public Offering |
Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering |
globenewswire.com |
2024-06-28 03:57:00 |
Czytaj oryginał (ang.) |
| Therapy developer Alumis seeks up to $1 bln valuation in US IPO |
Alumis is targeting a valuation of up to $1.01 billion in its initial public offering in the United States, the therapy developer said on Monday. |
reuters.com |
2024-06-24 12:27:17 |
Czytaj oryginał (ang.) |
| Alumis eyes $300 million in proceeds in IPO |
Biopharmaceutical company Alumis Inc. on Monday said it plans to offer 17.65 million shares at an estimated price range of $16 to $18 a share in its upcoming initial public offering. At the midpoint of its range, Alumis will raise about $300 million with underwriters Morgan Stanley, Leerink Partners, Cantor and Guggenheim Securities. |
marketwatch.com |
2024-06-24 11:18:00 |
Czytaj oryginał (ang.) |
| Alumis' $100 Million IPO: Promising Psoriasis Treatment Results |
Alumis Inc. has filed for a $100 million IPO to advance its later-Phase trials treatment programs. Lead candidate ESK-001 shows positive trial results for psoriasis treatment, driving potential demand for company shares. The global psoriasis treatment market forecasted to reach $44 billion by 2031, with Alumis seeking U.S. public capital market investment. |
seekingalpha.com |
2024-06-11 16:25:10 |
Czytaj oryginał (ang.) |